Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 541 to 550 of 1144 total matches.
Malathion for the Treatment of Head Lice
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999 (Issue 1059)
:267, 1986). These data and others suggest that a
two-hour treatment time or less may be sufficient ...
0.5% malathion in 78% isopropanol was recently approved by the FDA for treatment of head lice.
Cevimeline (Evoxac) For Dry Mouth
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000 (Issue 1084)
at the recommended dosage for Sjögren’s syndrome, according to AWP listings in
First DataBank PriceAlert, July 15 ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Newer Antihistamines
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001 (Issue 1103)
cost to the patient for 30 days’ treatment with the lowest recommended dosage for adults based on data ...
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the newer, non-sedating antihistamines.
GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device
The Medical Letter on Drugs and Therapeutics • May 14, 2001 (Issue 1104)
safety data are available.
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti, M.D., M.P.H ...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Initial Treatment of Parkinson's Disease:Wait Just a Minute
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001 (Issue 1108)
or 3 tablets daily
of a levodopa formulation, based on data from retail pharmacies nationwide provided ...
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Ophthalmic Cyclosporine (Restasis) for Dry Eyes
The Medical Letter on Drugs and Therapeutics • May 26, 2003 (Issue 1157)
and increase tear production in some patients with dry eye disease, but more convincing data are
needed. Since ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Azelaic Acid (Finacea) for Rosacea
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
% metronidazole cream (Noritate), according to data from retail
pharmacies nationwide provided by NDCHealth, July ...
Azelaic acid 15% gel (Finacea Berlex) is now available in the US for treatment of mild to moderate rosacea. A 20% cream formulation of the drug (Azelex Allergan; Medical Letter 1996; 38:52) has been marketed here since 1996 for treatment of acne. The effectiveness of Finacea compared to its own vehicle and to metronidazole gel is discussed. Information on the drug's mechanism of action, adverse effects, dosage and cost are also included.
Amlodipine/Atorvastatin (Caduet)
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004 (Issue 1186)
tablet/day, according to the most recent data (May 31, 2004) from retail pharmacies nationwide
available ...
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Atomoxetine (Strattera) Revisited
The Medical Letter on Drugs and Therapeutics • Aug 16, 2004 (Issue 1189)
was first marketed, until more
data become available, atomoxetine is best reserved for patients who ...
Atomoxetine (Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate (Concerta, and others) (Medical Letter 2003; 45:11). Since then, the drug has been heavily advertised directly to the public for use in both children and...
Drugs for Kidney Stones
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010 (Issue 1352)
) from the distal ureter. More data
from larger randomized trials would be welcome. o
1. EM Worcester and FL Coe ...
Renal colic is a common problem in emergency departments. Stones <5 mm in diameter often pass spontaneously; stones >10 mm in diameter generally do not. The usual treatment for stones that do not pass is ureteroscopy with laser lithotripsy or shockwave lithotripsy. Some clinicians have suggested that off-label use of an oral alpha-adrenergic blocker such as tamsulosin (Flomax, and others) or calcium channel blocker such as nifedipine (Procardia XL, and others) could be tried first, with or without a corticosteroid. Both adrenoreceptors and calcium channels may have a role in the...
